Delivering oxygen where blood cannot
90% of people suffering an acute stroke currently receive no direct treatment. Aurum's ABL-101 has the potential to increase treatment to the vast majority of stroke patients.
Most stroke patients receive no direct stroke treatment because the treatments that exist cannot reach enough patients fast enough and safely enough.
Aurum Biosciences is changing that. We are a UK clinical-stage company developing ABL-101, an injectable oxygen carrier 45 times smaller than a red blood cell — small enough to slip past the blockages and small collateral vessels that stop red blood cells in their tracks and carry oxygen directly to the tissue that is dying.
ABL-101 is both a therapy and a diagnostic. Two Phase 2 trials are underway in 2026, supported by Wellcome Trust and a growing international network of clinical collaborators.
Meet David
David is a co-founder and CEO of Aurum Biosciences having provided significant input into the development of ABL-101 both technically and commercially.
Hear his introduction.
ABL-101 - Diagnostic
> MRI Metabolic Imaging agent
providing acute stroke diagnostics
> MRI Inflammation Imaging
Uptake of ABL-101 by immune cells can be imaged
A Clinical Stage Company
> Phase 2 Acute Stroke Trial
Therapeutic/Diagnostic/Safety (India)
> Phase 2 Carotid Arteriosclerosis Imaging Trial
Diagnostic/Safety (Switzerland)
Stroke - Significant unmet medical need
Globally only 10% of patients are eligible for and receive treatment
> STROKE is the 2nd leading cause of death worldwide
> 1 in 4 PEOPLE will suffer a stroke in their lifetime
Aurum’s patented ABL-101 platform technology
has the potential to dramatically increase the number of stroke patients treated from 10% to nearer 100%, helping patients currently missing out during emergencies through its promise to help treat the stroke-related oxygen deprivation which can quickly cause brain damage.
Aurum’s lead product ABL-101 has undergone significant pre-clinical development and has completed early phase 1 and 2 human studies. ABL-101, is planned for phase 2 trials in stroke and inflammation imaging in 2026/27
